180 related articles for article (PubMed ID: 12526160)
1. Strategies to adapt adenoviral vectors for targeted delivery.
O'Riordan CR; Song A; Lanciotti J
Methods Mol Med; 2003; 76():89-112. PubMed ID: 12526160
[No Abstract] [Full Text] [Related]
2. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo.
Ogawara K; Rots MG; Kok RJ; Moorlag HE; Van Loenen AM; Meijer DK; Haisma HJ; Molema G
Hum Gene Ther; 2004 May; 15(5):433-43. PubMed ID: 15144574
[TBL] [Abstract][Full Text] [Related]
3. Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus.
Pereboeva L; Komarova S; Roth J; Ponnazhagan S; Curiel DT
Gene Ther; 2007 Apr; 14(8):627-37. PubMed ID: 17251987
[TBL] [Abstract][Full Text] [Related]
4. Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates.
Lanciotti J; Song A; Doukas J; Sosnowski B; Pierce G; Gregory R; Wadsworth S; O'Riordan C
Mol Ther; 2003 Jul; 8(1):99-107. PubMed ID: 12842433
[TBL] [Abstract][Full Text] [Related]
5. Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished.
van Beusechem VW; Grill J; Mastenbroek DC; Wickham TJ; Roelvink PW; Haisma HJ; Lamfers ML; Dirven CM; Pinedo HM; Gerritsen WR
J Virol; 2002 Mar; 76(6):2753-62. PubMed ID: 11861842
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus gene therapy for ovarian cancer.
Russell W
J Natl Cancer Inst; 2002 May; 94(10):706-7. PubMed ID: 12011212
[No Abstract] [Full Text] [Related]
7. A mosaic fiber adenovirus serotype 5 vector containing reovirus sigma 1 and adenovirus serotype 3 knob fibers increases transduction in an ovarian cancer ex vivo system via a coxsackie and adenovirus receptor-independent pathway.
Tsuruta Y; Pereboeva L; Glasgow JN; Rein DT; Kawakami Y; Alvarez RD; Rocconi RP; Siegal GP; Dent P; Fisher PB; Curiel DT
Clin Cancer Res; 2007 May; 13(9):2777-83. PubMed ID: 17473211
[TBL] [Abstract][Full Text] [Related]
8. Experimental treatment of ovarian cancers by adenovirus vectors combining receptor targeting and selective expression of tumor necrosis factor.
Murugesan SR; Akiyama M; Einfeld DA; Wickham TJ; King CR
Int J Oncol; 2007 Oct; 31(4):813-22. PubMed ID: 17786312
[TBL] [Abstract][Full Text] [Related]
9. Gene delivery into malignant glioma by infectivity-enhanced adenovirus: in vivo versus in vitro models.
Van Houdt WJ; Wu H; Glasgow JN; Lamfers ML; Dirven CM; Gillespie GY; Curiel DT; Haviv YS
Neuro Oncol; 2007 Jul; 9(3):280-90. PubMed ID: 17522331
[TBL] [Abstract][Full Text] [Related]
10. Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice.
Romanczuk H; Galer CE; Zabner J; Barsomian G; Wadsworth SC; O'Riordan CR
Hum Gene Ther; 1999 Nov; 10(16):2615-26. PubMed ID: 10566889
[TBL] [Abstract][Full Text] [Related]
11. Targeted adenovirus vectors.
Mizuguchi H; Hayakawa T
Hum Gene Ther; 2004 Nov; 15(11):1034-44. PubMed ID: 15610604
[TBL] [Abstract][Full Text] [Related]
12. In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus.
Hemminki A; Zinn KR; Liu B; Chaudhuri TR; Desmond RA; Rogers BE; Barnes MN; Alvarez RD; Curiel DT
J Natl Cancer Inst; 2002 May; 94(10):741-9. PubMed ID: 12011224
[TBL] [Abstract][Full Text] [Related]
13. Liposome-complexed adenoviral gene transfer in cancer cells expressing various levels of coxsackievirus and adenovirus receptor.
Lee EM; Hong SH; Lee YJ; Kang YH; Choi KC; Choi SH; Kim IH; Lim SJ
J Cancer Res Clin Oncol; 2004 Mar; 130(3):169-77. PubMed ID: 14677059
[TBL] [Abstract][Full Text] [Related]
14. Adenoviral vectors--new insights.
Nemerow GR
Trends Microbiol; 2000 Sep; 8(9):391-4. PubMed ID: 10989301
[No Abstract] [Full Text] [Related]
15. Effective gene transfer to human melanomas via integrin-targeted adenoviral vectors.
Nakamura T; Sato K; Hamada H
Hum Gene Ther; 2002 Mar; 13(5):613-26. PubMed ID: 11916485
[TBL] [Abstract][Full Text] [Related]
16. Use of a chimeric adenovirus vector enhances BMP2 production and bone formation.
Olmsted-Davis EA; Gugala Z; Gannon FH; Yotnda P; McAlhany RE; Lindsey RW; Davis AR
Hum Gene Ther; 2002 Jul; 13(11):1337-47. PubMed ID: 12162816
[TBL] [Abstract][Full Text] [Related]
17. Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer.
Green NK; Morrison J; Hale S; Briggs SS; Stevenson M; Subr V; Ulbrich K; Chandler L; Mautner V; Seymour LW; Fisher KD
J Gene Med; 2008 Mar; 10(3):280-9. PubMed ID: 18214996
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer.
Dehari H; Ito Y; Nakamura T; Kobune M; Sasaki K; Yonekura N; Kohama G; Hamada H
Cancer Gene Ther; 2003 Jan; 10(1):75-85. PubMed ID: 12489031
[TBL] [Abstract][Full Text] [Related]
19. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells.
Jung Y; Park HJ; Kim PH; Lee J; Hyung W; Yang J; Ko H; Sohn JH; Kim JH; Huh YM; Yun CO; Haam S
J Control Release; 2007 Nov; 123(2):164-71. PubMed ID: 17854941
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells.
Kim M; Zinn KR; Barnett BG; Sumerel LA; Krasnykh V; Curiel DT; Douglas JT
Eur J Cancer; 2002 Sep; 38(14):1917-26. PubMed ID: 12204675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
